Ribuvaptan

Drug Profile

Ribuvaptan

Alternative Names: BAY-86-8050

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Acetamides; Carbamates; Chlorophenols; Fluorocarbons; Heart failure therapies; Small molecules; Triazoles
  • Mechanism of Action Vasopressin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 02 Sep 2016 Ribuvaptan is still in phase I development in Germany
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Germany
  • 31 Dec 2011 Phase-I clinical trials in Heart failure in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top